The document is a valuable summary of the most recent and evidence-based information to assist healthcare professionals in managing patients experiencing bleeding on oral anticoagulation.
Clots are life-saving in the right place at the right time, when they can stop us bleeding to death. But a clot in the wrong place can spell disaster, leading to heart attack, stroke, deep vein thrombosis or pulmonary embolism. This article explains why life-threatening clots can develop so quickly, what can be done to prevent them, and how each type of clot is treated.
Venous thromboembolism (VTE) occurs when a blood clot forms in the wrong place, and it can cause serious illness or death. Treatment of VTE is currently very labour-intensive for nurses and awkward for patients. Novel treatments are more expensive and have their own risks. But this new approach is less reliant on nurse time and more straightforward for patients, and seems likely to become the norm during the next few years.
A new simple device has been designed to improve venous blood flow of people when seated and to help in the prevention, care and treatment of deep vein thrombosis and pulmonary embolism. The RBR legﬂow™ was created with the input of Professor Richard Beasley, director of the Medical Research Institute of New Zealand (MRINZ) and a world authority on respiratory medicine.
A new survey from the Atrial Fibrillation society shows a high level of demand for self-monitoring in people being treated with warfarin. In the survey, 79% of respondents said that they would prefer to self-monitor over clinic visits. New self- monitoring products are being launched.
A new study suggests that women on anticoagulant therapy are able to take hormonal contraception or HRT with no increased risk of recurrent venous thromboembolism (VTE) or abnormal uterine bleeding.
The direct factor Xa inhibitor rivaroxaban has been showing promise in trials in venous thromboembolism (VTE) and peripheral arterial disease (PAD). We provide details from the EINSTEIN CHOICE and COMPASS trials.
Thromboembolism is a common complication of heart disease – particularly in patients with atrial fibrillation (AF). Decisions to prescribe an anticoagulant are based on assessment of an individual patient's risk of clotting and the side-effects of treatment. With growing numbers of patients with heart disease, the number of patients on anticoagulants is increasing and there is a shift to primary care-based anticoagulation clinics. Practice nurses have a central role in educating patients about anticoagulation therapy and in monitoring their ongoing care.
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major public health problem affecting around 100 per 100,000 population per year and causing thousands of deaths annually. Large population-based studies have shown that factors associated with hospitalisation account for half of the attributable risk of VTE.